Literature DB >> 22936386

BRCA1 and microRNAs: emerging networks and potential therapeutic targets.

Suhwan Chang1, Shyam K Sharan.   

Abstract

BRCA1 is a well-known tumor suppressor implicated in familial breast and ovarian cancer. Since its cloning in 1994, numerous studies have established BRCA1's role in diverse cellular and biochemical processes, such as DNA damage repair, cell cycle control, and transcriptional regulation as well as ubiquitination. In addition, a number of recent studies have functionally linked this tumor suppressor to another important cellular regulator, microRNAs, which are short (19-22 nt) RNAs that were discovered in the nematode in 1993. Soon their presence and function were validated in mammals, and since then, the role of microRNAs has been actively investigated in almost all biological processes, including cancer. In this review, we will describe recent progress in the understanding of the BRCA1 function through microRNAs and the role of microRNAs in regulating BRCA1, with emphasis on the implication of these processes on the development and progression of cancer. We will also discuss the therapeutic potential of microRNA mimics or inhibitors of microRNAs to affect BRCA1 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936386      PMCID: PMC3887789          DOI: 10.1007/s10059-012-0118-y

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  80 in total

1.  NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies.

Authors:  Jimmy L Zhao; Dinesh S Rao; Mark P Boldin; Konstantin D Taganov; Ryan M O'Connell; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

2.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Authors:  Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza
Journal:  Lancet Oncol       Date:  2011-08-19       Impact factor: 41.316

3.  Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.

Authors:  Cory Pelletier; William C Speed; Trupti Paranjape; Katie Keane; Rachel Blitzblau; Antoinette Hollestelle; Kyan Safavi; Ans van den Ouweland; Daniel Zelterman; Frank J Slack; Kenneth K Kidd; Joanne B Weidhaas
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

4.  The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis.

Authors:  Tomoyuki Nakasa; Hayatoshi Shibuya; Yoshihiko Nagata; Takuya Niimoto; Mitsuo Ochi
Journal:  Arthritis Rheum       Date:  2011-06

5.  MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

Authors:  Shahana Majid; Sharanjot Saini; Altaf A Dar; Hiroshi Hirata; Varahram Shahryari; Yuichiro Tanaka; Soichiro Yamamura; Koji Ueno; Mohd Saif Zaman; Kamaldeep Singh; Inik Chang; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2011-02-17       Impact factor: 12.701

6.  Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Authors:  Diana M Cittelly; Partha M Das; Virgilio A Salvo; Juan P Fonseca; Matthew E Burow; Frank E Jones
Journal:  Carcinogenesis       Date:  2010-09-27       Impact factor: 4.944

7.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.

Authors:  Patryk Moskwa; Francesca M Buffa; Yunfeng Pan; Rohit Panchakshari; Ponnari Gottipati; Ruth J Muschel; John Beech; Ritu Kulshrestha; Kotb Abdelmohsen; David M Weinstock; Myriam Gorospe; Adrian L Harris; Thomas Helleday; Dipanjan Chowdhury
Journal:  Mol Cell       Date:  2010-12-30       Impact factor: 17.970

8.  MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis.

Authors:  Mariola Kurowska-Stolarska; Stefano Alivernini; Lucy E Ballantine; Darren L Asquith; Neal L Millar; Derek S Gilchrist; James Reilly; Michelle Ierna; Alasdair R Fraser; Bartosz Stolarski; Charles McSharry; Axel J Hueber; Derek Baxter; John Hunter; Steffen Gay; Foo Y Liew; Iain B McInnes
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

9.  Quantitative proteomics identify novel miR-155 target proteins.

Authors:  Christopher Lössner; Jan Meier; Uwe Warnken; Michael A Rogers; Peter Lichter; Armin Pscherer; Martina Schnölzer
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

10.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.

Authors:  Amandine I Garcia; Monique Buisson; Pascale Bertrand; Ruth Rimokh; Etienne Rouleau; Bernard S Lopez; Rosette Lidereau; Ivan Mikaélian; Sylvie Mazoyer
Journal:  EMBO Mol Med       Date:  2011-04-05       Impact factor: 12.137

View more
  21 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 2.  Levels of MicroRNA Heterogeneity in Cancer Biology.

Authors:  Nina Petrovic; Sercan Ergün; Esma R Isenovic
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

3.  Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.

Authors:  Jinghua Huang; Changxiu Lin; Hai Dong; Zhengri Piao; Chunhua Jin; Hengmin Han; Dongchun Jin
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-08       Impact factor: 3.333

4.  BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.

Authors:  E Kumaraswamy; K L Wendt; L A Augustine; S R Stecklein; E C Sibala; D Li; S Gunewardena; R A Jensen
Journal:  Oncogene       Date:  2014-11-24       Impact factor: 9.867

5.  Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Lijun Zhu; Erich M Sturgis; Hua Zhang; Zhongming Lu; Ye Tao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2017-07-07       Impact factor: 7.396

6.  BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.

Authors:  Weixing Zhao; Justin B Steinfeld; Fengshan Liang; Xiaoyong Chen; David G Maranon; Chu Jian Ma; Youngho Kwon; Timsi Rao; Weibin Wang; Chen Sheng; Xuemei Song; Yanhong Deng; Judit Jimenez-Sainz; Lucy Lu; Ryan B Jensen; Yong Xiong; Gary M Kupfer; Claudia Wiese; Eric C Greene; Patrick Sung
Journal:  Nature       Date:  2017-10-04       Impact factor: 49.962

7.  SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation.

Authors:  Elizabeth V Minten; Priya Kapoor-Vazirani; Chunyang Li; Hui Zhang; Kamakshi Balakrishnan; David S Yu
Journal:  Cell Rep       Date:  2021-03-30       Impact factor: 9.423

8.  MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.

Authors:  Katia Danza; Simona De Summa; Rosamaria Pinto; Brunella Pilato; Orazio Palumbo; Giuseppe Merla; Gianni Simone; Stefania Tommasi
Journal:  Oncotarget       Date:  2015-01-01

9.  Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs.

Authors:  Kevin Quann; Yi Jing; Isidore Rigoutsos
Journal:  Front Genet       Date:  2015-07-24       Impact factor: 4.599

Review 10.  Combinatorial Control of mRNA Fates by RNA-Binding Proteins and Non-Coding RNAs.

Authors:  Valentina Iadevaia; André P Gerber
Journal:  Biomolecules       Date:  2015-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.